Thomas (for Ed Arce)'s questions to Mirum Pharmaceuticals Inc (MIRM) leadership • Q4 2024
Question
Thomas, on behalf of Ed Arce, asked for the data timeline for the VISTAS study post-enrollment, patient experience in the EXPAND study, and if an interim analysis is planned for EXPAND.
Answer
CEO Chris Peetz estimated VISTAS top-line data would be available about six months after enrollment completion. CMO Joanne Quan cited positive compassionate use data in biliary atresia as a source of confidence for EXPAND and explicitly stated no interim analysis is planned, as it would delay full enrollment completion in 2026.